{"schema_version":"secwatch.filing_event.v1","accession":"0001384101-23-000161","form_type":"8-K","ticker":"VCYT","cik":"0001384101","company_name":"VERACYTE, INC.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.819236+00:00","generated_at":"2026-06-08T14:18:26.234945+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Veracyte Q3 2023 revenue up 19% to $90.1M; net loss widens on $34.9M impairment","bullets":["Total revenue $90.1M, +19% YoY; testing revenue $82.0M, +27% YoY.","Net loss $29.6M ($0.41 per share) vs $8.7M loss a year ago; includes $34.9M impairment from nCounter license.","Total test volume 32,544, +23% YoY.","Non-GAAP gross margin 69% vs 66% prior year; generated $14.2M cash from ops, cash $202.5M.","Management cites strong demand for Decipher Prostate and Afirma tests driving growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001384101-23-000161","json":"https://secwatch.observer/filing/0001384101-23-000161.json","markdown":"https://secwatch.observer/filing/0001384101-23-000161.md","text":"https://secwatch.observer/filing/0001384101-23-000161.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1384101/000138410123000161/0001384101-23-000161-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1384101/000138410123000161/vcyt-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T14:18:26.234945+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f2feca1abc1fbf73c635705b15b92d356e74b5d","claim":"VERACYTE, INC. reported the third quarter ended September 30, 2023 results: revenue $90.1 million, net income Net loss for the third quarter of 2023 was $29.6 million, EPS $0.41.","evidence_excerpt":"EX-99.1 (EX-99.1 PRESS RELEASE 11-07-2023) --- PRESS RELEASE 11-07-2023 Document Exhibit 99.1 Veracyte Announces Third Quarter 2023 Financial Results Grew Total Revenue to $90.1 million, an Increase of 19% Grew Testing Revenue by 27% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., November 7, 2023 --- Veracyte, Inc. (Nasdaq: VCYT)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1384101/000138410123000161/0001384101-23-000161-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$90.1 million"},{"label":"Net income","value":"Net loss for the third quarter of 2023 was $29.6 million"},{"label":"EPS","value":"$0.41"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}